AddLife AB (FRA:1AD1) Cyclically Adjusted Revenue per Share: €5.94 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1AD1 AddLife AB FRA:1AD1
87 GF Score
Price €14.67
GF Value €14.23
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AddLife AB Cyclically Adjusted Revenue per Share?

AddLife AB FRA:1AD1 +1.73% 87 Cyclically Adjusted Revenue per Share is €5.94 as of Jun. 2026. GuruFocus rates FRA:1AD1 with a GF Score™ of 87/100 and a GF Value™ of €14.23 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AddLife AB's adjusted revenue per share for the three months ended in Jun. 2026 was €2.037. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.94 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AddLife AB's average Cyclically Adjusted Revenue Growth Rate was 10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-02), AddLife AB's current stock price is €14.67. AddLife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €5.94. AddLife AB's Cyclically Adjusted PS Ratio of today is 2.47.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AddLife AB was 3.60. The lowest was 1.97. And the median was 2.76.


AddLife AB  (FRA:1AD1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AddLife AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.67/5.94
=2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AddLife AB was 3.60. The lowest was 1.97. And the median was 2.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AddLife AB Cyclically Adjusted Revenue per Share Related Terms


AddLife AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AddLife AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AddLife AB Cyclically Adjusted Revenue per Share Chart

AddLife AB Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 4.70 5.54

AddLife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.12 5.28 5.54 5.39 5.94

FRA:1AD1 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, AddLife AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AddLife AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AddLife AB's Cyclically Adjusted PS Ratio falls into.


FRA:1AD1
87GF Score
AddLife AB FRA:1AD1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AddLife AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AddLife AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.037/134.6100*134.6100
=2.037

Current CPI (Jun. 2026) = 134.6100.

AddLife AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.413 101.138 0.550
201612 0.614 102.022 0.810
201703 0.589 102.022 0.777
201706 0.572 102.752 0.749
201709 0.529 103.279 0.689
201712 0.659 103.793 0.855
201803 0.579 103.962 0.750
201806 0.596 104.875 0.765
201809 0.549 105.679 0.699
201812 0.677 105.912 0.860
201903 0.754 105.886 0.959
201906 0.703 106.742 0.887
201909 0.667 107.214 0.837
201912 0.840 107.766 1.049
202003 0.860 106.563 1.086
202006 1.060 107.498 1.327
202009 1.060 107.635 1.326
202012 1.482 108.296 1.842
202103 1.511 108.360 1.877
202106 1.856 108.928 2.294
202109 1.492 110.338 1.820
202112 1.674 112.486 2.003
202203 2.010 114.825 2.356
202206 1.610 118.384 1.831
202209 1.588 122.296 1.748
202212 1.697 126.365 1.808
202303 1.788 127.042 1.895
202306 1.663 129.407 1.730
202309 1.609 130.224 1.663
202312 1.866 131.912 1.904
202403 1.864 132.205 1.898
202406 1.857 132.716 1.884
202409 1.694 132.304 1.724
202412 2.010 132.987 2.035
202503 2.024 132.825 2.051
202506 1.921 133.699 1.934
202509 1.812 133.480 1.827
202512 2.061 133.390 2.080
202603 2.015 133.560 2.031
202606 2.037 134.610 2.037

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €5.94 mean?
AddLife AB (FRA:1AD1) has a Cyclically Adjusted Revenue per Share of €5.94 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AddLife AB and its competitors.
Is AddLife AB's Cyclically Adjusted Revenue per Share too high?
AddLife AB's current Cyclically Adjusted Revenue per Share is €5.94. Overall, AddLife AB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
AddLife AB's Cyclically Adjusted Revenue per Share of €5.94 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AddLife AB and its competitors. AddLife AB's current Cyclically Adjusted Revenue per Share is €5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
Based on GuruFocus' analysis, AddLife AB (FRA:1AD1) is currently considered Fairly Valued. The stock's GF Value™ is €14.23, compared to a current price of €14.67 — trading 3.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €5.94. AddLife AB's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AddLife AB (FRA:1AD1), the current Cyclically Adjusted Revenue per Share is €5.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AddLife AB (FRA:1AD1) Overvalued in 2026?

Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued. The current stock price of €14.67 is trading 3.1% above its estimated GF Value™ of €14.23. GuruFocus considers AddLife AB to be Fairly Valued.

Key valuation signals for FRA:1AD1:

  • Cyclically Adjusted Revenue per Share: €5.94
  • GF Value™: €14.23 vs. price of €14.67 (3.1% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AddLife AB Business Description

Address Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
87GF Score

Get the complete analysis for FRA:1AD1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.67
Price
€14.23
GF Value